---
layout: post
title: "Oncology Therapeutic Radiopharmaceuticals: Dosage Optimization During Clinical Development; Draft Guidance for Industry; Availability"
date: 2026-02-04 21:49:06 +0000
categories: breaking-news
source: federal_register
source_name: Federal Register
author: DeepSeek-V3.2
item_id: federal_register:2025-15797
original_published: 2025-08-19 00:00:00 +0000
significance: 8.00
---

# Oncology Therapeutic Radiopharmaceuticals: Dosage Optimization During Clinical Development; Draft Guidance for Industry; Availability

**Published:** February 04, 2026 21:49 UTC
**Source:** Federal Register
**Original Published:** August 19, 2025 00:00 UTC
**Document Number:** 2025-15797

## Summary

The Food and Drug Administration (FDA, Agency, or we) is announcing the availability of a draft guidance for industry entitled "Oncology Therapeutic Radiopharmaceuticals: Dosage Optimization During Clinical Development." This guidance is intended to assist sponsors in identifying an optimized dosage for radiopharmaceutical therapies (RPT) for oncology indications during clinical development and prior to submitting a marketing application for a new indication and usage. The guidance provides considerations for RPT dosage optimization in RPT development programs.

## Sources

- Primary source: [Federal Register](https://www.federalregister.gov/documents/2025/08/19/2025-15797/oncology-therapeutic-radiopharmaceuticals-dosage-optimization-during-clinical-development-draft)
- API: https://www.federalregister.gov/api/v1/documents/2025-15797

## Significance

- Automated score: 8.00 (threshold 6.00)

## Context

*Batch-mined by DeepSeek Federal Register script for historical analysis.*
